BATON ROUGE, La., February 9, 2023 (GLOBE NEWSWIRE) — Amedisys, Inc. AMEEDa leading provider of quality home health care, hospices, personal care and critical care, announced today that its board of directors has approved a stock repurchase program under which the company may repurchase up to $100 million of its outstanding common stock through December 31, 2023.

Scott Ginn, Acting Chief Operating Officer and Chief Financial Officer, stated, “Given our strong cash flow and low level of debt, we believe it would be prudent to have share buyback authorization later this year. This will become a recurring part of our capital deployment strategy; however, our priorities will continue to be value-added acquisitions in both our home health and hospice businesses, as well as building our high-acuity care joint ventures.”

Under the stock repurchase program, the Company may repurchase its common stock from time to time in quantities, at prices and at times the Company deems appropriate, subject to market conditions and other considerations and in accordance with applicable federal securities laws and other legal requirements. The Company’s repurchases may be conducted using open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program and/or a 10b5-1 trading plan.

About Amedisys:

Amedisys, Inc. is a leading home health care company providing personalized home health, hospice, personal care and critical care services. Amedisys focuses on providing the best care to our patients, be it home care; inpatient hospital, palliative and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after surgery or injury; care focused on empowering them to cope with a chronic illness; or hospice care at the end of life. More than 3,000 hospitals and 102,000 doctors across the country have chosen Amedisys as their partner in post-acute care. Founded in 1982, with headquarters in…